Drug Action
Apalutamide is an androgen receptor inhibitor that decreases tumour cell proliferation and increases apoptosis.
PDF page 1020
Loading InternPractice…
Drug reference
Apalutamide is an androgen receptor inhibitor that decreases tumour cell proliferation and increases apoptosis.
PDF page 1020
Prostate cancer (specialist use only) ▶BY MOUTH ▶Adult: 240 mg once daily, for dose adjustments due to side-effects—consult product literature
PDF page 1020
History or risk of seizures
PDF page 1020
History or risk of QT-interval prolongation. recent cardiovascular disease
PDF page 1020
→Appendix 1: apalutamide
PDF page 1020
▶Common or very common Arthralgia. autoimmune thyroiditis. bone fractures. conjunctivitis. costal cartilage fracture. dyslipidaemia. fall. fatigue. genital rash. hypothyroidism. oral disorders. rash pustular. sacrum fracture. skin reactions. weight decreased ▶Uncommon Seizure (discontinue permanently) ▶Frequency not known QT interval prolongation
PDF page 1020
Manufacturer advises men should use condoms in combination with another highly effective contraceptive method during treatment and for 3 months after stopping treatment if their partner is of childbearing potential.
PDF page 1020
Manufacturer advises avoid in severe impairment (no information available).
PDF page 1020
Manufacturer advises caution in severe impairment (no information available).
PDF page 1020
There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Erleada (Janssen-Cilag Ltd) A Apalutamide 60 mg Erleada 60mg tablets | 112 tablet P £2,735.00
PDF page 1020
240 mg once daily, for dose adjustments due to
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1020